Editas Medicine, Inc.

NasdaqGS:EDIT 株式レポート

時価総額：US$195.6m

Editas Medicine マネジメント

マネジメント 基準チェック /24

Editas Medicineの CEO はGilmore O’Neillで、 Jun2022年に任命され、 の在任期間は 2.42年です。 の年間総報酬は$ 2.39Mで、 26.8%給与と73.2%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.13%を直接所有しており、その価値は$ 257.01K 。経営陣と取締役会の平均在任期間はそれぞれ1.7年と3.9年です。

主要情報

Gilmore O’Neill

最高経営責任者

US$2.4m

報酬総額

CEO給与比率26.8%
CEO在任期間2.4yrs
CEOの所有権0.1%
経営陣の平均在職期間1.7yrs
取締役会の平均在任期間3.9yrs

経営陣の近況

Recent updates

Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding

Nov 20
Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding

Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week

Nov 06
Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Sep 26
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Editas Medicine: A Risk/Reward Worth Considering

Sep 25

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Aug 23
Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 10
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

May 12
Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Apr 23
The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Mar 09
Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Feb 28

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Dec 15
New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

May 10
Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Jan 19
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Oct 18

Editas Medicine started at neutral at BofA due to competition in gene editing programs

Sep 29

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Sep 13
We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies

Aug 23

Editas Medicine Q2 2022 Earnings Preview

Aug 02

Baisong Mei joins Editas Medicine as Chief Medical Officer

Jul 18

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Jun 12
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Editas: Tackling Rare Eye Disease With Use Of Crispr Technology

Jun 06

Editas: The Unforeseen Detrimental Effect Of Patent Win

Mar 25

Editas: CRISPR Gene Editing Biotech With Promising Future

Mar 15

CEO報酬分析

Editas Medicine の収益と比較して、Gilmore O’Neill の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$211m

Jun 30 2024n/an/a

-US$193m

Mar 31 2024n/an/a

-US$166m

Dec 31 2023US$2mUS$641k

-US$153m

Sep 30 2023n/an/a

-US$195m

Jun 30 2023n/an/a

-US$206m

Mar 31 2023n/an/a

-US$219m

Dec 31 2022US$9mUS$356k

-US$220m

報酬と市場: Gilmoreの 総報酬 ($USD 2.39M ) は、 US市場 ($USD 1.46M ) の同規模の企業の平均を上回っています。

報酬と収益: Gilmoreの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Gilmore O’Neill (60 yo)

2.4yrs

在職期間

US$2,392,309

報酬

Dr. Gilmore O’Neill, M.B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as i...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Gilmore O’Neill
President2.4yrsUS$2.39m0.13%
$ 257.0k
Erick Lucera
CFO & Executive VP1.5yrsUS$2.69m0.028%
$ 54.8k
Linda Burkly
Executive VP & Chief Scientific Officer1.3yrsUS$1.73m0.018%
$ 34.3k
Baisong Mei
Executive VP & Chief Medical Officer2.3yrsUS$1.14m0.052%
$ 100.9k
Feng Zhang
Co-Founder & Scientific Advisory Board Member11.8yrsデータなしデータなし
George Church
Co-Founder & Scientific Advisory Board Member11.8yrsデータなしデータなし
Gregory Whitehead
Executive VP and Chief Technical & Quality Officerless than a yearデータなしデータなし
Cristi Barnett
Corporate Communications & Investor Relationsno dataデータなしデータなし
Charlene Stern
Executive VP & General Counselno dataデータなしデータなし
Linea Aspesi
Executive VP & Chief People Officer1.7yrsデータなしデータなし
Caren Deardorf
Executive VP and Chief Commercial & Strategy Officer1.2yrsデータなしデータなし

1.7yrs

平均在職期間

60yo

平均年齢

経験豊富な経営陣: EDITの経営陣は 経験豊富 とはみなされません ( 1.7年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称ポジション在職期間報酬所有権
Gilmore O’Neill
Presidentno dataUS$2.39m0.13%
$ 257.0k
Feng Zhang
Co-Founder & Scientific Advisory Board Memberno dataデータなしデータなし
George Church
Co-Founder & Scientific Advisory Board Memberno dataデータなしデータなし
Emma Reeve
Independent Chairman of the Board3.2yrsUS$238.24k0%
$ 0
Andrew Hirsch
Independent Director7.5yrsUS$210.56k0.0024%
$ 4.7k
Jessica Hopfield
Independent Director6.8yrsUS$231.07k0.082%
$ 160.4k
Elliott Levy
Independent Director1.6yrsUS$264.88k0%
$ 0
David Scadden
Independent Director5.8yrsUS$213.06k0%
$ 0
Bernadette Connaughton
Independent Director3.1yrsUS$215.06k0%
$ 0
Meeta Chatterjee
Independent Director3.9yrsUS$205.56k0%
$ 0

3.9yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: EDITの 取締役会 は 経験豊富 であると考えられます ( 3.9年の平均在任期間)。